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The use of topical apraclonidine 0.5% in the diagnosis of 
Horner’s syndrome is gaining wide acceptance.1-3 Horner’s 
syndrome characteristically presents with the tetrad of ptosis, 
miosis, anhidrosis and apparent enophthalmos secondary to a 
reduced palpebral fissure from upper-lid ptosis and elevation 
of the lower lid, so-called inverted ptosis. A large spectrum of 
disorders both central and peripheral from the hypothalamus to 
the orbit may be implicated in Horner’s syndrome. While any 
of the 1st, 2nd or 3rd-order oculosympathetic neurons may be 
involved, the co-existence of cerebral, brainstem, spinal cord, 
brachial plexus, carotid, cavernous sinus or orbital signs aid 
enormously in localisation of lesions. Still, Horner’s syndrome 
per se remains a robust sign and is always ipsilateral to the le-
sion.   
Topical apraclonidine has been shown to have many 
advantages over the conventional use of topical cocaine 4% 
in confirming the presence of Horner’s syndrome. The lack 
of availability of cocaine 4% makes it an unpopular choice. 
Cocaine is a noradrenaline re-uptake inhibitor that results in 
increased noradrenaline levels at the neuromuscular junction 
of the normal pupil; hence mydriasis occurs in the normal 
pupil but not in the noradrenaline-deficient Horner’s pupil. 
Topical cocaine is a weak dilator of the normal pupil, with 
many documented failures. Being a controlled substance and 
an illegal recreational drug, patients may show reluctance 
regarding its use as a test agent.  Urine metabolites of cocaine 
are also present because of systemic absorption.2
Pharmacological confirmation of Horner’s syndrome is often 
needed because of the frequent co-existence of physiological 
anisocoria and mechanical ptosis, especially in the elderly. 
In children, the spectrum of causes varies from the benign 
congenital type to the highly malignant neuroblastoma.4 Topical 
apraclonidine has been shown to supersede cocaine for this 
purpose as it is readily available and adequately sensitive (87% 
sensitivity).5 Apraclonidine is a weak α1-agonist and a strong 
α2-agonist. Following Horner’s syndrome there is up-regulation 
of α1-receptors that increases apraclonidine sensitivity. In 
response to apraclonidine, the denervation supersensitivity 
results in pupillary dilatation and lid elevation on the abnormal 
side but no response or slight miosis on the normal side 
from α2-activity.5 The presynaptic α2-activity, which inhibits 
the release of noradrenaline, is negligible in the presence of 
noradrenaline deficiency in the Horner’s pupil.5 The effect of 
apraclonidine is most evident 30 minutes after instillation when 
the result should be interpreted. Pilocarpine 0.125% used for the 
testing of Holmes-Adie pupil works on the similar principle of 
denervation supersensitivity within the oculo-parasympathetic 
system.
A 75-year-old man experienced a transient ischaemic attack 
while driving; he suddenly lost focus on the road ahead and 
the scenery in front of him seemed to expand. He stopped his 
vehicle and sought help. He had difficulty with reading for the 
rest of the day but made a full recovery. He had well-controlled 
hypertension, no diabetes mellitus and no hyperlipidaemia and 
was a teetotaller. Clinical examination revealed a well person 
with hypertension, symmetrical carotid pulses and no bruits. 
He had a right Horner’s syndrome and other cranial nerves 
were intact. There was no pyramidal tract, sensory or cerebellar 
signs and his gait was also normal. Computed tomography 
(CT) scan of the brain demonstrated a right caudate nucleus 
lacunar infarct. Chest radiograph, full blood count, urea and 
electrolytes, blood glucose, liver function tests and lipid profile 
were normal. Carotid doppler studies demonstrated normal 
flow and no stenosis but vertebral doppler studies were 
suboptimal. Nevertheless, the clinical impression was that of 
vertebro-basilar ischaemia.  
Fig. 1 shows pre- and post-apraclonidine instillation. The 
relative mydriasis and reversal of ptosis on the abnormal right 
side following apraclonidine confirm the presence of right 
Horner’s syndrome. The relative miosis induced in the normal 
pupil is the result of apraclonidine on presynaptic α2-receptors. 
Brainstem infarction was suspected as a cause for the patient’s 
Horner’s syndrome.
Topical apraclonidine is useful in confirming the presence 
of Horner’s syndrome. Its mydriatic effect on the abnormal 
pupil makes for easier interpretation, as seen in Fig. 1. In acute 
cases false-negative results may be obtained since the effect of 
apraclonidine is dependent on up-regulation of α1-receptors, 
which takes between 5 and 8 days to develop.3 Therefore 
apraclonidine is recommended as first-line agent in testing 
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and if there is no response in the acute 
setting, cocaine is considered as the 
alternative.1
Topical apraclonidine is currently 
used for reduction of intra-ocular 
pressure in acute angle closure 
glaucoma and following YAG laser 
therapy. Because of the weak α1-
activity it has been shown to be useful 
in diagnosing Horner’s syndrome 
regardless of the site of the lesion. 
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Fig. 1. Before (above) and 30 minutes after 
apraclonidine.
The Medicines Control Council (MCC) alerts health care profes-
sionals to new prescribing information for promethazine.
The package inserts for promethazine-containing products 
are currently being updated to reflect a contraindication to use 
in children under the age of 2 years because of the potential for 
fatal respiratory depression in this age group.
Serious life-threatening cases of respiratory depression, 
including fatalities, have been reported with promethazine 
use in paediatric patients under 2 years of age.1-3 Promethazine 
should therefore not be administered to children under 2 years 
of age, and with caution to children of 2 years and older, and 
the lowest effective dose should be used in this group.2
Promethazine is used as an antihistamine, sedative, or 
anti-emetic.  There are several over-the-counter products 
that contain promethazine. These include antihistamines, 
combination analgesics/antipyretic paediatric syrups, 
and cough and cold preparations. Prescribers and users of 
these products should check the ingredients and review the 
revised package insert and patient information leaflet before 
prescribing or using promethazine-containing products.
Health care professionals are encouraged to report any 
adverse reactions associated with the use of medicines to 
the MCC’s National Adverse Drug Event Monitoring Centre 
(NADEMC) by telephone (021 447-1618) or fax (021 448-6181).
National Drug Event Monitoring Centre
Medicines Control Council
Cape Town 
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Roche, in agreement and co-operation with health authorities 
(EMEA and Swissmedic), is recalling all batches of Viracept 
powder and tablets in Europe and some other regions of the 
world. The USA, Canada and Japan are not affected by this 
recall.
Roche has received several reports that some batches of 
Viracept 250 mg tablets have a strange odour. A detailed 
chemical analysis of the affected tablets showed they contain 
higher than normal levels of methane sulfonic acid ethyl ester. 
In the interests of patient safety Roche has decided to recall all 
batches of Viracept tablets and powder currently on the market. 
In South Africa, Roche is working closely with the Medicines 
Control Council in the process of recalling the products. 
Roche has also proactively frozen all stock of the powder and 
tablets at distributor and wholesaler levels, and is in the process 
of extending this to pharmacy level.
In South Africa it is estimated that less than 200 patients 
received Virecept therapy in the last year.  Patients are 
requested to contact their doctors to discuss alternative 
therapies.
For further information contact Vuyo Piti, Roche Communications 
Manager, tel. 011 928-8860, email: vuyo.piti@roche.com 
Roche recalls Viracept due to chemical impurity
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